Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ilico Genetics is developing the first methylated DNA-based blood test for early detection of gastric cancer. The test can identify tumors or pre-cancerous lesions years before symptoms appear or before traditional endoscopy would detect them. It offers dynamic monitoring over time, reduces treatment costs by up to 90% compared to late-stage interventions, and is designed for broad screening due to its non-invasive nature and low cost. The company has demonstrated promising results in initial studies but has not yet reached commercial launch.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ilico Genetics.